Additionally, such disabilities are often affected by constraints in the physical environment. Įvidence suggests that these clinical impairments promote difficulty walking in real-world environments, either at home or in the community. Indeed, nearly half of people with PD regularly experience freezing of gait (FOG), reaching about 80% of the people severely affected. For instance, progressive loss of postural reflexes leads to balance impairments and gait disturbances, common features among these patients that are found to be associated with increased risk of falls and injury, decreased mobility, and reduced quality of life and survival. PD is characterized by the development of disabling motor and non-motor symptoms over time. Therefore, the burden of this disease on patients, caregivers, and healthcare systems will rise, representing a growing challenge to society. As a reflection of increased life expectancy and other factors, the number of individuals living with this condition is expected to increase considerably over the next decades, with the prevalence likely to double by the year 2030 among people over the age of 50. Parkinson’s disease (PD) is a chronic progressive neurodegenerative disorder affecting about 1% of people over the age of 60, with a prevalence as high as 4% in older populations. Journal: Journal of Parkinson's Disease, vol. Keywords: Parkinson’s disease, architecture, design, systematic review, qualitative evidence synthesis
Ferreira, MD, PhD, Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina de Lisboa, Av. | Centro de Investigação em Arquitetura, Urbanismo e Design (CIAUD), Faculdade de Arquitetura, Universidade de Lisboa, Lisbon, PortugalĬorrespondence to: Prof. | Department of Medicine, Parkinson’s Disease and Movement Disorders Center, Division of Neurology, The Ottawa Hospital Research Institute, University of Ottawa Brain and Mind Institute, Ottawa, Ontario, Canada | Department of Neuroscience Rita Levi Montalcini, University of Torino, Turin, Italy | CNS –Campus Neurológico Sénior, Torres Vedras, Portugal | Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa.Īvenida Professor Egas Moniz, 1649-028, Lisboa, Portugal
| Serviço de Anestesiologia, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
a c d *Īffiliations: Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal f | Costa, João a c | Ramos, Tânia Beisl g | Ferreira, Joaquim J. a c | Bouça-Machado, Raquel c d | Fabbri, Margherita c e | Mestre, Tiago A. Authors: Ramos, Joana Beisl a b | Duarte, Gonçalo S.
0 kommentar(er)
